Publications by authors named "Clare J Wilhem"
Article Synopsis
- The HER2 gene mutations and amplifications lead to increased tumor growth by hyperactivating the HER2 receptor tyrosine kinase, but its internalization and ubiquitination are crucial for the effectiveness of certain anti-HER2 therapies, particularly in lung cancer.
- A clinical trial showed a 51% response rate for the drug ado-trastuzumab emtansine (T-DM1) in non-small cell lung cancer patients with HER2 alterations, and using irreversible pan-HER inhibitors can further improve treatment outcomes.
- Switching from T-DM1 to trastuzumab deruxtecan (T-DXd) offers durable responses in cases where resistance develops, indicating potential advancements in the
